Handheld ultrasound, B-natriuretic peptide for screening stage B heart failure

Southern Medical Journal

Volumn 103, Issue 7, 2010, Pages 616-622

  Hebert, Kathy ^a   Horswell, Ron ^b   Heidenreich, Paul ^b   Miranda, Jennifer ^b   Arcement, Lee ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

BNP; handheld ultrasound; heart failure; stage B

Indexed keywords

NATRIURETIC PEPTIDE RECEPTOR B;

ADULT; AREA UNDER THE CURVE; ARTICLE; DIABETIC PATIENT; DIAGNOSTIC ACCURACY; DIASTOLIC DYSFUNCTION; ECHOGRAPHY; ENZYME BLOOD LEVEL; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; SCREENING; STAGING; SYSTOLIC DYSFUNCTION;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OBSERVER VARIATION; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; ROC CURVE; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 77954244738     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181e1ffec     Document Type: Article

References (23)

1. American Heart Association. Heart Disease and Stroke Statistics-2008 Update. Dallas, American Heart Association, 2008.
2. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. Chronic disease overview. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Atlanta (GA), 2008. Available at: http://www.cdc.gov/ nccdphp/overview.htm. Accessed June 19, 2009.
3. California Health Care Foundation. Health care costs 101. Oakland (CA), 2006. Available at: http://www.chcf.org/documents/insurance/HealthCare Costs06.pdf. Accessed June 19, 2009.
4. Denavas-Walt C, Proctor BD, Smith JUS. Census Bureau, Current Population Reports, p60-233, Income, Poverty and Health Insurance Coverage in the United States: 2006. Washington, DC: U.S. Government Printing Office, 2007.
5. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Engl J Med 1991;325:293-302.
6. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med 1992;327:685-691.
7. Zugck C, Haunstetter A, Kruger C, et al. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 2002;39:1615-1622.
8. Heidenreich PA, Gubens MA, Fonarow GC, et al. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004;43: 1019-1026.
9. Doust JA, Glasziou PP, Pietrzak E, et al. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-1984.
10. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-391.
11. Maisel AS, Krishnaswamy P, Nowak RM, et al; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
12. Schocken DD, Arrieta MI, Leaverton PE, et al. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992;20:301-306.
13. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA 2006;296:2209-2216.
14. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
15. Fauci AS, Braunwald E, Kasper DL, et al (eds). Harrison's Principles of Internal Medicine. New York, McGraw-Hill, 2008.
16. SPSS for Windows, Rel. 11.0.1 2001. Chicago: SPSS Inc., 2001. Available at: http://www.spss.com/statistics. Accessed July 10, 2009.
17. Davis RC, Hobbs FD, Kenkre JE, et al. Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: Community based epidemiological study. BMJ 2002;325:1156.
18. Epshteyn V, Morrison K, Krishnaswamy P, et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003;26:2081-2087.
19. McKie PM, Rodeheffer RJ, Cataliotti A, et al. Amino-terminal pro-Btype natriuretic peptide and B-type natriuretic peptide: Biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006;47:874-880.
20. Marcovina SM, Crea F, Davignon J, et al. Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools. J Intern Med 2007;261:214-234.
21. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-982.
22. Taylor JA, Christenson RH, Rao K, et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006; 152:1071-1076.
23. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43: 1590-1595.